- Home
- SRRK vs BHC Comparison
SRRK vs BHC Comparison
Compare SRRK & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRRK
- BHC
- Stock Information
- Founded
- SRRK 2012
- BHC N/A
- Country
- SRRK United States
- BHC Canada
- Employees
- SRRK N/A
- BHC N/A
- Industry
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- BHC Biotechnology: Pharmaceutical Preparations
- Sector
- SRRK Health Care
- BHC Health Care
- Exchange
- SRRK Nasdaq
- BHC Nasdaq
- Market Cap
- SRRK 2.8B
- BHC 3.0B
- IPO Year
- SRRK 2018
- BHC N/A
- Fundamental
- Price
- SRRK $26.49
- BHC $8.59
- Analyst Decision
- SRRK Strong Buy
- BHC Hold
- Analyst Count
- SRRK 7
- BHC 4
- Target Price
- SRRK $34.00
- BHC $7.25
- AVG Volume (30 Days)
- SRRK 984.5K
- BHC 2.0M
- Earning Date
- SRRK 11-12-2024
- BHC 10-30-2024
- Dividend Yield
- SRRK N/A
- BHC N/A
- EPS Growth
- SRRK N/A
- BHC N/A
- EPS
- SRRK N/A
- BHC N/A
- Revenue
- SRRK N/A
- BHC $9,474,000,000.00
- Revenue This Year
- SRRK N/A
- BHC $9.59
- Revenue Next Year
- SRRK N/A
- BHC $3.53
- P/E Ratio
- SRRK N/A
- BHC N/A
- Revenue Growth
- SRRK N/A
- BHC 10.91
- 52 Week Low
- SRRK $6.76
- BHC $3.96
- 52 Week High
- SRRK $35.38
- BHC $11.46
- Technical
- Relative Strength Index (RSI)
- SRRK 50.87
- BHC 49.98
- Support Level
- SRRK $25.86
- BHC $9.19
- Resistance Level
- SRRK $28.11
- BHC $9.49
- Average True Range (ATR)
- SRRK 1.68
- BHC 0.37
- MACD
- SRRK -0.92
- BHC -0.09
- Stochastic Oscillator
- SRRK 11.71
- BHC 33.24
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
About BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.